Fig. 7

The combination treatment of KU-177 and BTZ extends the survival of 5TMM3VT MM mice. A KU-177 greatly extended the survival of 5TMMVT mice. B The combination of KU-177 and BTZ significantly improved the survival time of 5TMMVT mice. C Time course of tumor growth originated from ANBL6 WT/DR cells in NOD-SCID mice treated with KU-177 or untreated. D Mean tumor weight of ANBL6 WT/DR xenografts from KU-177-treated or untreated group at day 37 after injection of MM cells. E Photographic images of xenografts in NOD-SCID mice of each group. F Graphic working model illustrates that AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in MM. The data are expressed as mean ± SD.*p<0.05, **p<0.01, ***p<0.001